Concepedia

Volker Schettler

VS

Statistics

Publications

35

Citations

1.6K

H-Index

20

Active since

1992

Affiliations

University of Göttingen(Current)

Kempten University of Applied Sciences

Technische Universität Dresden

University Hospital Carl Gustav Carus

Agaplesion Markus Hospital

Volker Schettler is an author at University of Göttingen specializing in medicine, lipid-lowering therapy, and lipid apheresis.

ORCID

Publications per year

1992–2024

35

Publications

35

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease

E. Roeseler, Ulrich Julius, Franz Heigl et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2016 · 212 citations · Full text

, , +16

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

, , +17

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

Patrick M. Moriarty, Klaus G. Parhofer, Stephan P. Babirak et al. · European Heart Journal · 2016 · 196 citations · Full text

, , +14

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

, , +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

, , +14

1–5 of 35